Jushi Holdings (JUSHF) Cash from Financing Activities (2021 - 2026)
Jushi Holdings' (JUSHF) quarterly Cash from Financing Activities came in at $11.1 million in Q1 2026, up 228.4% year-on-year from $3.4 million in Q1 2025, and up 540.69% on a QoQ basis from -$2.5 million in Q4 2025.
Jushi Holdings (JUSHF) Cash from Financing Activities (2021 - 2026) Analysis & Trends
Jushi Holdings (JUSHF) has 6 years of Cash from Financing Activities data on file, last reported at $11.1 million in Q1 2026.
- On a quarterly basis, Cash from Financing Activities rose 228.4% year-over-year to $11.1 million in Q1 2026; TTM through Mar 2026 was $8.5 million, a 158.31% increase from a year earlier, with the FY2025 full-year figure at $767000.0, up 103.14% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $11.1 million, up from -$2.5 million in the prior quarter.
- Over the last five years, Cash from Financing Activities for JUSHF reached as high as $20.1 million in Q2 2023 and fell as low as -$13.7 million in Q3 2024.
- Historically, Cash from Financing Activities has averaged $2.1 million across 5 years, with a median of -$262000.0 in 2025.
- Across the five-year window, Cash from Financing Activities tumbled 4971.21% in 2023 and soared 228.4% in 2026, its largest moves.
- Year by year, Cash from Financing Activities stood at -$2.1 million in 2022, then sank by 59.51% to -$3.3 million in 2023, then jumped by 56.86% to -$1.4 million in 2024, then plunged by 74.91% to -$2.5 million in 2025, then soared by 540.69% to $11.1 million in 2026.
- Per Business Quant data, the three most recent Cash from Financing Activities figures were $11.1 million in Q1 2026, -$2.5 million in Q4 2025, and $166000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -840.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -494.13 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -1.48 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -203.80 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -86.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -65.00 Mn |
| 10 | Jushi Holdings | 81.25 Mn | 41.54 Mn | 29.88 Mn | 11.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.12 Mn |
| Mar 31, 2026 | 11.12 Mn |
| Dec 31, 2025 | -2.52 Mn |
| Dec 31, 2025 | -2.52 Mn |
| Sep 30, 2025 | 166,000.00 |
| Sep 30, 2025 | 166,000.00 |
| Jun 30, 2025 | -262,000.00 |
| Jun 30, 2025 | -262,000.00 |
| Mar 31, 2025 | 3.39 Mn |
| Mar 31, 2025 | 3.39 Mn |
| Dec 31, 2024 | -1.44 Mn |
| Dec 31, 2024 | -1.44 Mn |
| Sep 30, 2024 | -13.74 Mn |
| Sep 30, 2024 | -13.74 Mn |
| Jun 30, 2024 | -2.78 Mn |
| Jun 30, 2024 | -2.78 Mn |
| Mar 31, 2024 | -6.49 Mn |
| Mar 31, 2024 | -6.49 Mn |
| Dec 31, 2023 | -3.35 Mn |
| Dec 31, 2023 | -3.35 Mn |